Cardiac Progenitor Cell Isolation via pRb Fluorescent Markers

The patent uses fluorescent markers (GFP, RFP, DsRed) that cause cells to emit different colors based on their genetic modification status. Cardiac progenitor cells are identified by their specific fluorescent color signatures, enabling precise visual identification and isolation without complex procedures. This color-based identification system directly resolves the contradiction by providing high identification accuracy through simple fluorescent detection.

The patent combines multiple functions into a single integrated system: cardiac progenitor cells are genetically modified to express fluorescent markers AND contain integrated pRb reporter constructs that simultaneously report both cell identity and regenerative potential. This merging allows clinicians to assess both cell identification and regeneration prediction in one imaging session, resolving the contradiction by making the additional measurement part of the standard procedure rather than a separate step.

The patent engineers cardiac progenitor cells with self-service capabilities: they are pre-loaded with genetic circuits that automatically respond to mild Rb/ARF inhibition by activating proliferation programs. The cells themselves perform the complex molecular pathway modulation when exposed to standard pharmaceutical agents, eliminating the need for complex delivery systems. This resolves the contradiction by making the cells themselves the vehicle for precise pathway targeting.

The patent creates universal cardiac progenitor cell constructs that simultaneously provide multiple functions: fluorescent tracking, pRb pathway reporting, and proliferation control all through a single genetic modification platform. The same viral vector system delivers all necessary genetic elements, making the cell preparation process standardized and efficient. This multi-functionality resolves the contradiction by consolidating multiple complex steps into one unified cell engineering protocol.